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Level of kidney function as a risk factor for cardiovascular group of the population is at risk for progression of
outcomes in the elderly. kidney disease and development of end-stage renal dis-
Background. There is a high prevalence of both reduced ease (ESRD); however, they are at even greater risk forkidney function as well as cardiovascular disease (CVD) in the
development of cardiovascular disease (CVD) [1]. Theelderly. We evaluated whether the level of kidney function is
reason for this is not entirely clear but is partly relatedan independent risk factor for CVD outcomes in the Cardiovas-
cular Health Study (CHS), a cohort of subjects whose age at to an excess prevalence of traditional cardiovascular risk
baseline was 65 years old or older. factors, such as hypertension and diabetes, in patients
Methods. Cox proportional-hazards regression was used to
with reduced GFR [2].evaluate the association of predicted glomerular filtration rate
Studies of high-risk patients, such as those who already(GFR) with CVD after adjustment for the major CVD risk
factors. We searched for nonlinear relationships between GFR have CVD or have many risk factors for CVD, have
and CVD, as well as interactions between level of kidney func- suggested that level of kidney function is a risk factor
tion and major CVD risk factors on CVD. for CVD outcomes [3–7]. In community studies, in whichResults. A total of 4893 subjects with predicted GFR of 15
patients were not selected for being at high risk for CVD,to 130 mL/min/1.73 m2 were included in the analysis. Fifty-six
results have been inconclusive. The level of kidney func-percent were female and the mean age was 73.4 years. Of the
subjects, 549 (11.2%) died and 1229 (25.1%) experienced CVD tion was not found to be a risk factor for CVD outcomes
events in 5.05 years of follow-up. Each 10 mL/min/1.73 m2 in the Framingham cohort or in NHANES I [8, 9], but
lower GFR was associated with an adjusted hazard ratio for
was found to be a risk factor for cardiovascular deathCVD, de novo CVD, recurrent CVD and all-cause mortality
in an analysis of the NHANES II data [10]. Studies ofof 1.05 (1.02, 1.09), 1.07 (1.01, 1.12), 1.04 (0.99, 1.09), and 1.06
(1.00, 1.12), respectively. There was no significant interaction both high- and low-risk populations have in general been
between level of GFR and other traditional CVD risk factors limited by measurement of kidney function as a binary
on CVD outcomes. A linear model best described the relation- variable, use of serum creatinine as the measure of kid-ship between GFR and CVD.
ney function, insufficient adjustment for prevalent CVDConclusion. The level of GFR is an independent risk factor
and well-recognized CVD risk factors, and absence offor CVD, de novo CVD, and all-cause mortality in the elderly.
evaluation for nonlinear relationships between the level
of kidney function and CVD outcomes.
Data from the National Health and Nutrition Exami- From a public health standpoint, it is especially impor-
nation Survey (NHANES) III suggest that there are tant to evaluate the relationship between level of kidney
more than 8 million people in the United States with function and CVD in the elderly. The elderly population
reduced kidney function defined by glomerular filtration is increasing and has a high prevalence of subjects with
rate (GFR) less than 60 mL/min/1.73 m2 [1]. This sub- reduced kidney function and CVD. For example, data
from NHANES III suggest that as many as 6.6 million
people in the United States older than 60 years of ageKey words: kidney disease, glomerular filtration rate, cardiovascular
disease. have a GFR less than 60 mL/min/1.73 m2 [1], while ap-
proximately 19% of individuals between 60 and 80 years
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The Cardiovascular Health Study (CHS) is a commu- and GFR is expressed as mL/min/1.73 m2. CHS serum
creatinine data were calibrated to The Cleveland Clinicnity-based cohort study. The cohort represents a suitable
study group to evaluate the relationship between level (where serum creatinine was measured in the MDRD
Study) indirectly by using NHANES III data. Since bothof kidney function and CVD in the elderly because the
subjects were not selected for being at high risk for CVD NHANES III and CHS were designed as representative
samples of the population, and NHANES III data have[12]. Fried et al [13] have shown in a previous analysis
been directly compared to the MDRD Study samplesthat a serum creatinine greater than 1.2 mg/dL is a risk
[16], it was assumed that the mean serum creatinine forfactor for all-cause mortality in this cohort. In the current
a given age, gender, and race should be comparable inanalysis, we particularly focused on CVD as the primary
the two studies. A linear regression of data combiningoutcome and sought to address many of the limitations
the two studies showed that serum creatinine levels wereof prior studies.
0.11 mg/dL higher among CHS participants during the
baseline examination than among NHANES III partici-
METHODS pants after adjustment for age, gender, and race and
Design limiting the analysis to individuals 66 to 90 years old
who are Caucasian or African American and had a serumThe CHS is a community-based longitudinal study of
creatinine less than 2.0 mg/dL at baseline. This valueadults 65 years old and older at baseline. The objective
was subtracted from serum creatinine before applicationof the study was the evaluation of risk factors for devel-
of the MDRD Study equation (shown above) in orderopment and progression of CHD and stroke [12]. A main
to obtain a more valid estimate of GFR.cohort of 5201 study participants was recruited between
Our objective was to evaluate the association of kid-1989 and 1990 from four communities in the United
ney function with CVD in subjects with GFR betweenStates: Sacramento County, California; Forsyth County,
15 and 130 mL/min/1.73 m2. We chose this range for twoNorth Carolina; Washington County, Maryland; and Al-
reasons. First, a GFR of 15 mL/min/1.73 mm2 is definedlegheny County, Pennsylvania [14]. Eligible participants
as kidney failure in the National Kidney Foundationwere sampled from Medicare eligibility lists in each area.
(NKF) Kidney Disease Outcomes Quality InitiativeThe subjects in the main cohort were examined yearly
(KDOQI) guidelines [1]. Seven subjects had GFR lessfrom 1989 through 1994 with an extensive follow-up for
than 15 mL/min/1.73 mm2. Second, a GFR of 130 mL/ascertainment of CVD (which we defined as myocardial
min/1.73 m2 is the upper limit of normal for GFR in theinfarction, coronary angioplasty, coronary artery bypass
elderly [17–19], and values above this range (N  199)graft, angina pectoris, heart failure, cardiac death, pe-
are likely less accurate estimates of level of kidney func-ripheral vascular disease, stroke, and transient ischemic
tion in this population. The study population thereforeattack) events and all-cause mortality. Mean follow-up
included 4893 subjects.time in the public use database was 4.33 years. Details
Baseline characteristics included demographics (age,of recruitment and the study have been extensively de-
ethnicity, gender, educational level, and income); life-scribed elsewhere [12, 14].
style (smoking, alcohol, exercise intensity); past medicalThe present study is a secondary analysis of the CHS
history [diabetes mellitus, hypertension, left ventricularpublic use data on 5135 subjects (66 did not consent for
hypertrophy (LVH) by electrocardiogram]; medicationtheir data to be included in the public use data set) to
use (beta blockers, diuretics, digoxin, angiotensin-con-ascertain the relationship of baseline kidney function to
verting enzyme inhibitors, calcium channel blockers andCVD outcomes and all-cause mortality. Serum creati-
aspirin); laboratory variables [albumin, creatinine, totalnine measurements were available on 5099 subjects and
cholesterol, high-density lipoprotein (HDL) cholesterol,were measured in a central laboratory using the Jaffe
low-density lipoprotein (LDL) cholesterol, triglycerides,method. The GFR was estimated using a simplified pre-
lipoprotein (a), fibrinogen, uric acid, and hematocrit];diction equation derived from the Modification of Diet
physical examination (weight, body mass index, bodyin Renal Disease (MDRD) Study [15] (abstract: Levey
surface area, systolic and diastolic blood pressure), andet al, J Am Soc Nephrol 11:A0828, 2000) and given by
baseline CVD. The methods employed by the CHS in-the following equation:
vestigators to assess baseline CVD have been described
GFR  186.3  (serum creatinine1.154) in detail elsewhere [20].
The outcomes of interest included (1) CVD during
 (age0.203)
follow-up; (2) de novo CVD (defined as CVD events
 1.212 (if African American) in subjects without baseline CVD); (3) recurrent CVD
(defined by CVD events in patients with baseline CVD);
 0.742 (if female)
and (4) All-cause mortality. We present the results for
all-cause mortality but do not discuss the details as causesSerum creatinine is measured in mg/dL, age in years,
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of death other than CVD were not available in the public of the relationship between level of kidney function and
use data. We chose the composite end point rather than CVD. Curvilinear associations of GFR were tested by
specific categories of CVD in order to optimize the statis- including a quadratic term and retaining it when signifi-
tical power. Details of the methodology employed by cant (P value  0.05), and by fitting parametric smooth-
the CHS investigators for the surveillance and ascertain- ing splines with five knots (0.05, 0.275, 0.5, 0.725, and
ment of CVD events have been described elsewhere [21]. 0.95 quantiles of GFR) corresponding to GFR values of
45.3, 64.0, 76.2, 88.5, and 107.3 mL/min/1.73 m2, respec-
Statistical analysis tively, to determine the functional form of GFR that
Means, standard deviations, and percentages were best explained its relationship to CVD. The results were
used to describe the baseline characteristics. Data were displayed by graphing the 3-year predicted probability
stratified into three groups by level of kidney function: of CVD versus GFR. A smoothing function was used to
GFR, 90 to 130 mL/min/1.73 m2, 60 to 89 mL/min/1.73 show how the average predicted probability varied by
m2, and 15 to 59 mL/min/1.73 m2. P values for linear GFR. Since the prediction for each individual included
trends were used to compare baseline data between these their 26 baseline covariates it was considered unadjusted.
groups. The cut points for the three groups were chosen Adjusted predicted probabilities at a given GFR were
as they represent the different stages of GFR as defined obtained by assuming all cohort members had this given
by the KDOQI chronic kidney disease guidelines [1]; that GFR (for example, 60 mL/min/1.73 m2) and calculating
is, normal GFR, mild decrease in GFR, and moderate to the average 3-year predicted probability across the entire
severe decrease in GFR. cohort [22]. Values were calculated in 5 mL/min/1.73 m2
Kaplan-Meier survival analysis was used to compare increments and the results graphed versus GFR using a
survival times between the three groups stratified by smoothing function. Adjusted values for a linear model
level of kidney function. The log-rank statistic was used and a cubic spline model were compared graphically to
to test for differences between groups. Cox proportional each other and the unadjusted risk.
hazards regression was used to explore the relationship We also evaluated for interactions between predicted
of CVD, de novo CVD, recurrent CVD, and survival GFR as a continuous variable with major CVD risk fac-
time to the baseline variables mentioned above, as well tors (as defined above). The relative risk for the various
as to predicted GFR. Factors considered in univariate outcomes was estimated from the adjusted hazard ratios.
analysis included all variables described in Table 1. Data was analyzed using the SAS Version 8.1. Micro-
Multivariable models were constructed and estimated soft Excel 97 and S-Plus were used for graphs and tables.
GFR was modeled as a continuous variable and as a Testing was two-sided and P values less than 0.05 were
categorical variable with KDOQI cut points defining
considered significant.
three groups of GFR: 15 to 59 mL/min/1.73 m2, 60 to 89
mL/min/1.73 m2, and 90 to 130 ml/min/1.73m2.
Analyses were initially adjusted for nonmodifiable fac- RESULTS
tors (age, gender, and race) and subsequently for base- Baseline characteristics
line variables that were significantly related to CVD, de
The baseline characteristics of the 4893 subjects arenovo CVD, recurrent CVD, and survival time in univari-
given in Table 1. The mean creatinine was 0.9 mg/dLate analyses (P 0.05), as well as major CVD risk factors
with a range of 0.5 to 3.9 mg/dL, and the baseline pre-(age, gender, race, presence of diabetes, HDL and LDL
dicted GFR was 75.4 mL/min/1.73 m2, with a range ofcholesterol, systolic blood pressure, smoking and LVH).
15.6 to 129.4 mL/min/1.73 m2. The mean age was 73.4Models were formally tested for assumptions of propor-
years and 56% and 4.3% were females and Africantional hazards by using a time-varying coefficient model
Americans, respectively. At baseline, 25.5%, 19.6%, 4.4%,and evaluating the P values for global and individual
5.7%, and 2.7% of the subjects had CVD, CHD, heartcovariates.
failure, cerebrovascular disease, and peripheral vascularWe then performed three sensitivity analyses. First,
disease, respectively.we repeated the above analyses using serum creatinine
(rather than estimated GFR) as the continuous variable
Association of reduced kidney function with otherof interest. Second, we repeated the above analyses in-
baseline factorscluding subjects with GFR between 130 and 200 mL/
The proportion of subjects in the stratified GFRmin/1.73 m2 (N  196). Third, we repeated the analyses
groups was 21% in the group with GFR 90 to 130 mL/calculating the hazard as a function of baseline age,
min/1.73 m2, 55.5% in the group with GFR 60 to 89 mL/rather than follow-up time. These three analyses were
min/1.73 m2, and 23.4% in the group with GFR 15 to 59performed primarily to confirm the internal consistency
mL/min/1.73 m2 with the mean GFR in the stratifiedof our results.
We then performed analyses to define the best form groups being 101.8, 75.8, and 50.8 mL/min/1.73 m2, re-
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Table 1. Baseline characteristics of study population
GFR 15 to 59 GFR 60 to 89 GFR 90 to 130 GFR 15 to 130 (Total)
mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2
(N  1145) (N  2716) (N  1032) (N  4893) P value
Baseline variables 50.88.6 75.88.7 101.89.4 75.419.2 trend
Demographics
Age 75.16.2 73.65.3 71.15.0 73.45.6 0.001
Female 52.6 52.6 66.3 55.5 0.001
African-American 3.3 3.3 8.4 4.3 0.001
Education (high school and lower) 31.5 26.3 27.8 27.8 0.045
Income (less than $50,000/year) 86.7 85.5 85.8 85.8 0.548
Physical characteristics
Weight kg 72.512.7 72.312.9 70.913.4 72.112.9 0.006
Hip circumference cm 101.48.0 101.37.9 101.48.4 101.38.0 0.979
Body surface area m2 1.80.2 1.80.2 1.70.2 1.80.2 0.001
Body mass index kg/m2 26.33.8 26.33.8 26.44.2 26.33.9 0.861
Lifestyle
Smoking pack-years 20.129.3 18.026.6 18.326.6 18.627.3 0.114
Alcohol drinks/week 1.84.6 2.96.9 3.520.9 2.711.1 0.001
Exercise low intensity or none 60.3 53.4 55.9 55.5 0.029
Baseline disease
Diabetes mellitus 24.1 19.7 26.2 22.1 0.327
Hypertension 55.3 38.2 36.2 41.8 0.001
Coronary heart disease 26.2 19.3 13.2 19.6 0.001
Heart failure 7.8 3.6 2.5 4.4 0.001
Cerebrovascular disease 10.1 4.9 3.0 5.7 0.001
Peripheral vascular disease 5.1 2.0 1.8 2.7 0.001
Left ventricular hypertrophy by ECG 7.0 3.9 2.9 4.4 0.001
Baseline cardiovascular disease 36.4 24.1 17.1 25.5 0.001
Clinical characteristics
Systolic blood pressure mm Hg 138.023.4 135.221.5 134.620.8 135.721.9 0.001
Diastolic blood pressure mm Hg 69.912.3 70.011.6 70.011.8 70.011.8 0.896
Laboratory measures
Albumin g/dL 4.010.30 4.010.29 3.980.27 4.00.29 0.061
Creatinine mg/dL 1.30.3 0.90.1 0.70.1 0.90.3 0.001
Total cholesterol mg/dL 211.141.9 211.038.9 211.737.7 211.239.4 0.743
HDL cholesterol mg/dL 50.815.2 53.615.2 56.816.8 53.615.7 0.001
LDL cholesterol mg/dL 133.637.7 133.335.3 131.834.6 133.035.7 0.243
Triglycerides mg/dL 153.580.4 140.674.1 136.581.2 142.877.4 0.001
Lipoprotein(a) mg/L 57.153.3 53.558.9 50.945.3 53.855.0 0.008
Fibrinogen mg/dL 332.168.9 316.965.2 319.362.8 321.065.9 0.001
Uric acid mg/dL 6.61.7 5.61.4 5.11.3 5.71.5 0.001
Hematocrit % 41.74.4 42.43.7 41.93.5 42.13.9 0.160
Medications
Diuretics 41.4 24.2 21.6 27.7 0.001
Angiotensin-converting enzyme inhibitors 11.4 5.9 4.5 6.9 0.001
Beta blockers 19.0 12.0 10.5 13.3 0.001
Calcium channel blockers 15.5 11.1 9.2 11.7 0.001
Aspirin 35.9 33.5 32.9 33.9 0.131
Lipid lowering medications 5.9 4.6 5.4 5.1 0.543
Abbreviations are: HDL cholesterol, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. Continuous variables are presented as mean 
SD while categorical variables are expressed as percent. P values for linear trend between glomerular filtration rate (GFR) groups (columns 2 to 4).
spectively. In the lower GFR group, only 37 (0.7%) sub- GFR groups were on diuretics, angiotensin-converting
jects had GFR values between 15 and 30 mL/min/1.73 m2. enzyme inhibitors, beta blockers and calcium channel
The prevalence of baseline CVD and risk factors for blockers.
CVD tended to increase in the groups with lower base-
Outcomesline GFR (Table 1). Thus the presence of baseline CHD,
heart failure, cerebrovascular disease, peripheral vascu- The mean (median) and maximum duration of follow-
up in the public use data were 4.33 (4.48 years) and 5.05lar disease, diabetes mellitus, hypertension and LVH
were highest in the group with GFR 15 to 59 mL/min/ years, respectively. There were 549 (11.2%) deaths. Of
these, 241 (43.8%) were directly attributable to cardiac1.73 m2. Patients with lower GFR were older and had
higher systolic blood pressure. They also had higher tri- or cerebrovascular causes. There was a total of 1229 CVD
events. Percentages of patients who experienced CHD,glycerides, fibrinogen, and uric acid, but lower HDL
cholesterol. A higher percentage of subjects in the lower heart failure, cerebrovascular disease, and peripheral vas-
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Table 2. All-cause mortality and cardiovascular disease (CVD) events and rates stratified by level of kidney function
GFR 15 to 59 GFR 60 to 89 GFR 90 to 130 GFR 15 to 130 (Total)
mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 mL/min/1.73 m2 P value
CVD
% Events 35.5% (407/1145) 23.4% (636/2716) 18.0% (186/1032) 25.1% (1229/4893) 0.001
Person-years at risk 4004 10,603 4206 18,813
Events per 1000 person-years 101.6 60.0 44.2 65.3
De novo CVDa
% Events 22.4% (163/728) 16.3% (336/2062) 12.4% (106/856) 16.6% (605/3646) 0.001
Person-years at risk 2803 8521 3628 14,952
Events per 1000 person-years 58.2 39.5 29.2 40.5
Recurrent CVDb
% Events 58.5% (244/417) 45.9% (300/654) 45.5% (80/176) 50.0% (624/1247) 0.001
Person-years at risk 1193 2066 570 3829
Events per 1000 person-years 204.5 145.2 140.3 163.0
All-cause mortality
% Events 19.0% (217/1145) 9.4% (254/2716) 7.6% (78/1032) 11.2% (549/4893) 0.001
Person-years at risk 4765 11,871 4512 21,148
Events per 1000 person-years 45.5 21.4 17.3 26.0
CVD is de novo CVD plus recurrent CVD. P values are for the log rank test for the Kaplan-Meier survival analysis between glomerular filtration rate (GFR)
groups (columns 2 to 4).
a Events in subjects without baseline CVD
b Events in subjects with baseline CVD
cular disease events were 13.4%, 4.4%, 5.8%, and 1.5% Sensitivity analyses
of patients, respectively. When serum creatinine was used as the primary mea-
Patients with lower GFR had a higher percentage of sure of level of kidney function each 0.1 mg/dL higher
CVD events and all-cause mortality (Table 2). There were serum creatinine was associated with an adjusted hazard
605 (16.6%) CVD events in subjects without baseline CVD (95% CI, P) for CVD, de novo CVD, recurrent CVD, and
and 624 (50%) events in subjects with baseline CVD. all-cause mortality of 1.04 (1.01, 1.06, P  0.001), 1.05
Kaplan-Meier survival analysis showed a greater proba- (1.01, 1.08, P  0.008), 1.03 (1.01, 1.06, P  0.02), and
bility of CVD, de novo CVD, recurrent CVD events, and 1.04 (1.01, 1.07, P  0.008), respectively.
all-cause mortality in patients with lower GFR (Fig. 1). If subjects with GFR between 130 and 200 mL/min/
1.73 m2 are included in the analysis using the level ofMultivariable models
GFR as a categorical variable, the results are essentially
After stratification into three groups by level of GFR, unchanged. That is, the fully adjusted hazard ratio (CI)
the fully adjusted hazard ratios for CVD, de novo CVD,
in subjects with GFR of 15 to 59 mL/min/1.73 m2 com-
and all-cause mortality were significantly higher in sub-
pared with the reference group (GFR of 90 mL/min/jects with GFR of 15 to 59 mL/min/1.73 m2 compared
1.73 m2) for CVD, de novo CVD, recurrent CVD, andto subjects with GFR of 90 to 130 mL/min/1.73 m2 (the
all-cause mortality were 1.28 (1.04, 1.57), 1.31 (1.00, 1.72),reference group) (Table 3). In subjects with GFR of 60
1.14 (0.86, 1.52), and 1.37 (1.00, 1.88), respectively.to 89 mL/min/1.73 m2, the fully adjusted hazard ratios
If subjects with GFR between 130 and 200 mL/min/for CVD and de novo CVD were also higher than the
1.73 m2 are included in the analysis using GFR as a con-reference group, although the results were not statisti-
tinuous variable, the hazard ratios (CI) for every 10 mL/cally significant (Table 3). The test for assumption of
min/1.73 m2 lower GFR are essentially the same for CVDproportional hazards was met for all outcomes.
and recurrent CVD, but weaker for de novo CVD [1.04When considering GFR as a continuous variable and
(0.99, 1.08)] and all-cause mortality [1.03 (0.99, 1.08)].after adjusting for traditional CVD risk factors as well
Subjects with GFR between 130 and 200 mL/min/1.73as variables significant in univariate analysis in the fixed
m2 had mean (SD) serum creatinine of 0.5 (0.06) mg/dL,Cox proportional hazards models, GFR was a significant
mean (SD) age of 71.2 (4.1) years, were predominantlyrisk factor for CVD, de novo CVD, and all-cause mortal-
female (86%), and had a slightly higher risk of events.ity (Table 3). A 10 mL/min/1.73 m2 lower GFR was as-
We suspect that the MDRD formula may not be an ac-sociated with an adjusted hazard ratio (95% CI, P) for
curate estimate of GFR in this subgroup of subjects. ThatCVD, de novo CVD, and all-cause mortality of 1.05
is, these subjects may have low muscle mass resulting in(1.02, 1.09, P  0.005), 1.07 (1.01, 1.12, P  0.012), and
a falsely elevated estimated GFR, and the higher risk is1.06 (1.00, 1.12, P  0.04), respectively. A 10 mL/min/
likely due to comorbid conditions associated with low1.73 m2 lower GFR was associated with an adjusted haz-
ard ratio of 1.04 (0.99, 1.10, P 0.088) for recurrent CVD. muscle mass such as malnutrition.
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Fig. 1. Analysis of cardiovascular disease (CVD) stratified by level of glomerular filtration rate (GFR). (A) Kaplan-Meier survival analysis for
CVD. (B) Kaplan-Meier survival analysis for de novo CVD. (C ) Kaplan-Meier survival analysis for recurrent CVD. (D) Kaplan-Meier survival
analysis for all-cause mortality.
Finally, we performed a sensitivity analysis calculating tent with the latter in that it demonstrates the similarity
the hazard as a function of age, rather than follow-up between the adjusted cubic spline and linear models.
time. The results were essentially unchanged.
Interactions
Nonlinear associations with CVD There was no significant interaction between level of
The 3-year probability of CVD events as a function kidney function measured as a continuous variable, with
of baseline GFR is shown in Figure 2. Without adjust- age, gender, race, presence of diabetes mellitus, systolic
ment for covariates, the probability of developing CVD or diastolic blood pressure, smoking, HDL and LDL
increases markedly below a GFR of70 mL/min/1.73 m2. cholesterol, or LVH with CVD outcomes.
After adjustment for covariates, the effect of GFR on
CVD is diminished but remains present. For example,
DISCUSSIONthe 3-year probability of CVD increases from 15% to
Our results demonstrate that a lower level of kidney21% with a decrease in GFR from 130 mL/min/1.73 m2
function is associated with a marked increase in the prob-to 30 mL/min/1.73 m2. The nonparametric smoothing
ability of CVD over 3 years. We also found that levelmethod led us to explore both linear and piece-wise
of kidney function is an independent risk factor for CVDlinear form of GFR. The quadratic term was not signifi-
outcomes, as well as all-cause mortality in the elderly.cant. A GFR value of 69 mL/min/1.73 m2 was found to
This is true in both continuous as well as categoricalbe the optimum knot point of a two-slope model based
analysis, as well as in subjects without prevalent CVD.on maximizing the log likelihood. The resulting two-
Finally, we noted that a linear model best described theslope model (relative hazard of 1.02 for every 10 mL/
relationship between GFR and CVD.min/1.73 m2 decrease in GFR above 69 mL/min/1.73 m2
Prior studies in high-risk populations have suggestedand 1.10 for every 10 mL/min/1.73 m2 decrease in GFR
that the level of kidney function is a risk factor for CVDbelow 69 mL/min/1.73 m2) was not however statistically
better than a one-slope linear model. Figure 2 is consis- outcomes [3–7]. For example, a post hoc analysis of the
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Table 3. The effect of level of kidney function on cardiovascular disease (CVD), de novo CVD, and recurrent CVD
Glomerular filtration rate (GFR) stratified into three groups
Unadjusted hazard ratio Partially adjusted hazard ratioa Adjusted hazard ratio
Outcomes Kidney function [95% C.I.] P value [95% C.I.] P value [95% C.I.] P value
CVDd 15 to 59 mL/min/1.73 m2 2.29 [1.93, 2.72], 0.001 1.75 [1.47, 2.10], 0.001 1.31 [1.06, 1.62], 0.013
60 to 89 mL/min/1.73 m2 1.36 [1.15, 1.60], 0.001 1.12 [0.95, 1.32], 0.197 1.10 [0.91, 1.32], 0.313
90 to 130 mL/min/1.73 m2 1.0 (reference)b 1.0 (reference)b 1.0 (reference)b
De-Novo CVDe 15 to 59 mL/min/1.73 m2 2.00 [1.57, 2.55], 0.001 1.53 [1.18, 1.96], 0.001 1.38 [1.04, 1.84], 0.026
60 to 89 mL/min/1.73 m2 1.37 [1.09, 1.68], 0.004 1.11 [0.89, 1.39], 0.344 1.23 [0.98, 1.56], 0.079
90 to 130 mL/min/1.73 m2 1.0 (reference)b 1.0 (reference)b 1.0 (reference)b
Recurrent CVDf 15 to 59 mL/min/1.73 m2 1.46 [1.13, 1.88], 0.003 1.26 [0.97, 1.63], 0.084 1.12 [0.84, 1.49], 0.460
60 to 89 mL/min/1.73 m2 1.04 [0.81, 1.33], 0.758 0.92 [0.72, 1.19], 0.537 0.88 [0.67, 1.15], 0.348
90 to 130 mL/min/1.73 m2 1.0 (reference)b 1.0 (reference)b 1.0 (reference)c
All-cause mortalityg 15 to 59 mL/min/1.73 m2 2.68 [2.07, 3.47], 0.001 1.68 [1.28, 2.20], 0.001 1.47 [1.05, 2.06], 0.024
60 to 89 mL/min/1.73 m2 1.25 [0.97, 1.61], 0.089 0.90 [0.69, 1.16], 0.406 1.05 [0.78, 1.41], 0.764
90 to 130 mL/min/1.73 m2 1.0 (reference)b 1.0 (reference)b 1.0 (reference)b
GFR as a continuous variable
CVDd Per 10 mL/min/1.73 m2 decrease in GFR 1.18 [1.15, 1.22], 0.001 1.12 [1.09, 1.16], 0.001 1.05 [1.02, 1.09], 0.005
Denovo CVDe Per 10 mL/min/1.73 m2 decrease in GFR 1.14 [1.00, 1.19], 0.001 1.08 [1.04, 1.13], 0.001 1.07 [1.01, 1.12], 0.012
Recurrent CVDf Per 10 mL/min/1.73 m2 decrease in GFR 1.10 [1.06, 1.15], 0.001 1.07 [1.03, 1.12], 0.001 1.04 [0.99, 1.10], 0.088
All-cause mortalityg Per 10 mL/min/1.73 m2 decrease in GFR 1.24 [1.19, 1.30], 0.001 1.13 [1.08, 1.19], 0.001 1.06 [1.00, 1.12], 0.047
a Adjusted for age, gender, and race
b P for the trend between GFR groups 0.05
c P for the trend between GFR groups 0.144
d Full model adjusted for age, gender, race, baseline CVD, hypertension, diabetes mellitus, left ventricular hypertrophy by ECG, smoking status, alcohol intake,
income level, educational level, activity level, weight, body surface area, systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol,
triglycerides, fibrinogen, uric acid, hematocrit, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and aspirin
e Full model adjusted for age, gender, race, hypertension, diabetes mellitus, left ventricular hypertrophy by electrocardiogram, smoking status, activity level,
educational level, weight, body surface area, systolic and diastolic blood pressure, high-density lipoprotein cholesterol, triglycerides, fibrinogen, uric acid, hematocrit,
diuretics, calcium channel blockers, and aspirin
f Full model adjusted for age, gender, race, activity level, smoking status, alcohol intake, systolic and diastolic blood pressure, high-density lipoprotein cholesterol,
triglycerides, fibrinogen, uric acid, left ventricular hypertrophy by electrocardiogram, diabetes mellitus, hypertension, diuretics, angiotensin-converting enzyme
inhibitors, and calcium channel blockers
g Full model adjusted for age, gender, race, baseline CVD, hypertension, diabetes mellitus, left ventricular hypertrophy by electrocardiogram, smoking status,
alcohol intake, income level, educational level, activity level, body mass index, hip circumference, systolic blood pressure, total cholesterol, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, lipoprotein (a), albumin, fibrinogen, uric acid, diuretics, angiotensin-converting enzyme inhibitors, calcium channel
blockers, and aspirin
Fig. 2. Smoothed 3-year predicted probabil-
ity of developing cardiovascular disease (CVD)
by level of glomerular filtration rate (GFR).
Unadjusted curve shows the risk incorporat-
ing each individual’s value for 26 covariates
in Table 3. Adjusted curve shows the average
risk in the Cardiovascular Health Study (CHS)
population if everyone had the GFR value on
the x-axis. The linear model include GFR as
a continuous variable in a Cox regression
while the cubic spline includes a cubic transi-
tion between linear segments with knots (at
0.05, 0.275, 0.5, 0.725, and 0.95 quantiles of
GFR) corresponding to GFR values of 45.3,
64.0, 76.2, 88.5, and 107.3 mL/min/1.73 m2, re-
spectively. Tick marks along the x-axis indicate
GFR values for individual participants (the
marks form a solid bar in GFR regions with
many individuals). A lower GFR cutoff of 30
mL/min/1.73 m2 was chosen because only 37
subjects had GFR values between 15 and 30
mL/min/1.73 m2; therefore the data were less
precise in the latter range.
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Studies of Left Ventricular Dysfunction (SOLVD) data- extended and more severe hypertension and therefore
suffered more vascular damage secondary to hyperten-base [5] has shown that the level of kidney function is
an independent risk factor for CVD mortality, while a sion. Unfortunately, our ability to appreciate subtle vas-
cular damage or subclinical CVD is not very sensitive;post hoc analysis of the Heart Outcomes Prevention and
Evaluation (HOPE) Study [4] showed that a creatinine therefore, although we can control for hypertension at
one point in time, we may be unable to control for pathol-1.4 mg/dL or a creatinine clearance 65 mL/min was
associated with worse cardiac outcomes in subjects with ogy induced by hypertension. Third, a decrease in the
level of kidney function may be associated with an in-either vascular disease or diabetes, as well as an addi-
tional CVD risk factor. creased level of nontraditional CVD risk factors such as
homocysteine or inflammatory mediators [28, 29] thatStudies in lower-risk populations have been less con-
clusive [8–10, 23–25]. Although the Hypertension Detec- were not measured and therefore not adjusted for in our
analysis. Finally, reduced kidney function itself may betion and Follow-up Program [26] found an association
between serum creatinine1.7 mg/dL and CVD mortal- a risk factor for progression of ventricular remodeling
and cardiac dysfunction [30]; that is, kidney disease mayity, and a baseline serum creatinine of1.5 mg/dL was as-
sociated with CVD outcomes in the Hypertension Opti- alter sodium and fluid handling and thereby cardiac func-
tion. Unfortunately, our retrospective analyses cannotmal Treatment Study [23], baseline serum creatinine was
not a risk factor for CVD outcomes in the Multiple Risk differentiate among these four possibilities.
There are three potential limitations of our analyses.Factor Intervention Trial (MRFIT) [25], the Framing-
ham Offspring Study [8], or NHANES I [9]. These data First, we were unable to control for center effect. The
public-use database does not provide center informationhave led some to propose that the association of kidney
function with CVD outcomes may be modified by the because of concern of confidentiality. We cannot com-
pletely overcome this limitation, but have endeavored toprior risk of the population being studied [27].
Many previous studies that have evaluated the rela- control for all variables that may track with center loca-
tionship between level of kidney function and CVD have tion such as education, ethnicity, income, and numerous
been limited by insufficient adjustment for traditional other comorbid conditions. Second, it is well recognized
risk factors or prevalent CVD [7, 26]; use of serum creati- that albuminuria is associated with the presence of LVH
nine as the measure of kidney function [8, 26], evaluation [31] and is a powerful independent risk factor for both
of kidney function only as categorical variable [4, 8, 10, the progression of kidney disease, as well as for the
26], and in those studies where continuous variables have development of CVD [32, 33]. Unfortunately, urinalyses
been used, lack of exploration of nonlinear relationships were not available in the public use data, therefore we
between level of kidney function and CVD outcomes could not adjust for albuminuria. Third, indirect calibra-
[5]. In our analysis, we attempted to account for these tion of serum creatinine to the NHANES III study is
limitations. We also wished to provide an estimate of not as precise as a direct comparison. However, this
the absolute increase in risk for CVD in patients with calibration resulted in GFR estimates that are similar to
reduced GFR, as well as the adjusted risk ascribed solely estimates of GFR using iothalamate clearance measure-
to changes in GFR. ments [16].
We found a large absolute increase in risk of CVD as- From a public health standpoint it is important to
sociated with decreased GFR. That is, subjects with GFR emphasize the size of the elderly population that is at
90 mL/min/1.73 m2 had a 15% risk of CVD over 3 years higher risk. Six point six million elderly persons in the
while subjects with GFR 30 mL/min/1.73 m2 had a 40% United States have GFR levels less than 60 mL/min/1.73
risk of CVD. This increase in risk is partly due to an m2 [1], the cut point used for many of the analyses in
increased prevalence of CVD and CVD risk factors in this manuscript. A level of GFR of 60 mL/min/1.73 m2
patients with reduced GFR (Table 1), but it is also due is approximately equivalent to a calibrated serum creati-
to an independent contribution ascribed solely to differ- nine concentration of 1.2 mg/dL in a 73-year-old Cauca-
ences in GFR (Fig. 2). sian man and 0.9 mg/dL in a 73-year-old Caucasian
There are a number of possibilities why the level of woman. This is in contrast to a higher serum creatinine
kidney function may be an independent risk factor for cut-off level used in analyses of many other studies [4, 26].
CVD outcomes. First, level of kidney function may be
a marker of undiagnosed vascular disease or alternatively
CONCLUSIONa marker for the severity of diagnosed vascular disease
In conclusion, the level of kidney function is an inde-in the elderly. Second, and somewhat related, level of
pendent risk factor for CVD, de novo CVD, and all-kidney function may be a measure of residual confound-
cause mortality in elderly subjects. Elderly patients withing from traditional CVD risk factors. For example, al-
reduced GFR should be considered at high risk for CVDthough we have controlled for hypertension, the individ-
ual with the lower GFR may be the one who has had and all-cause mortality.
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